[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PDUFA_Pulse PDUFA Pulse

PDUFA Pulse posts on X about $mdgl, $galt, $akro, $amgn the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXX -XX%
• X Month XXXXXX -XX%
• X Months XXXXXX +838%
• X Year XXXXXX +71%

Mentions: X #

• X Week XX -XX%
• X Month XX -XXXX%
• X Months XX +833%
• X Year XX +564%

Followers: XXX #

• X Week XXX +4.20%
• X Month XXX +30%
• X Months XXX +154%
• X Year XXX +172%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence stocks XXXXX% cryptocurrencies XXXXX%

Social topic influence $mdgl 5.88%, $galt 5.88%, $akro 5.88%, $amgn 5.88%, $agio 5.88%, checkpoint 5.88%, $kura 5.88%, $beam 5.88%, $jnj 5.88%, os XXXX%

Top accounts mentioned or mentioned by @runlolarn

Top assets mentioned Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Akropolis (AKRO) Amgen, Inc. (AMGN) Agios Pharmaceuticals, Inc. (AGIO) BEAM (BEAM) Johnson & Johnson (JNJ) Muhdo Hub (DNA)

Top Social Posts

Top posts by engagements in the last XX hours

"Nov XX - $MDGL Rezdiffra (resmetirom MASH) PoA XX % The NASH kingpin reports again. Phase X follow-ups for Rezdiffra. $XX B cap $XXX M cash burn. $GALT $AKRO"
X Link 2025-11-10T18:35Z XXX followers, XXX engagements

"📈 THE 6-MONTH REVOLUTION: Amgen & GSK aim to kill the daily pill.The second half of December isn't just about approval; it's about Lifestyle Leverage. 🧠 Dec 14: $AMGN (Amgen) Uplizna (gMG) The Edge: While competitors like Vyvgart require frequent infusions Uplizna brings a twice-yearly dosing schedule to Myasthenia Gravis. In a crowded neurology market convenience is the ultimate moat. 🫁 Dec 16: $GSK Depemokimab (Asthma & CRSwNP) The Edge: The First Ultra-Long-Acting Biologic.We are talking about switching from daily inhalers/pills to just two shots a year. Indication 1: Severe Asthma"
X Link 2025-12-03T18:18Z XXX followers, XXX engagements

"PDUFA TODAY: Agios $AGIO Pyrukynd Label Expansion (/-thalassemia) The Analyst View: Agios is testing the regulatory ceiling for its hematology franchise. While approval probabilities are high (directional 70%) the real alpha lies in the label language. A narrow indicationor a label burdened with restrictive surveillancewill cap the commercial ramp. The Market Structure Risk: Entering the second liquid week of December we are in a "Repricing Vacuum." Institutional bids thin out daily. In this structure failure (CRL) triggers an air-pocket decline while success (Approval) often faces muted"
X Link 2025-12-07T15:58Z XXX followers, 1246 engagements

"Big news from #SABCS25: BioNTech + Bristol Myers Squibb just dropped promising Phase X data for pumitamig a PD-L1 VEGF-A bispecific in pretreated triple-negative breast cancer.Key highlights: Encouraging ORR and PFS in a tough-to-treat population Potential first-in-class combo hitting both immune checkpoint and angiogenesis Another step forward for patients with TNBC who desperately need new options. #Oncology #Immunotherapy #BreastCancer Full data presented today in San Antonio"
X Link 2025-12-09T13:38Z XXX followers, XXX engagements

"🧬 Forget the Santa Rally its ASH Season. The American Society of Hematology (ASH) meeting kicks off this weekend (Dec 6-9) and the abstracts are already moving markets. While we watch the PDUFA calendar keep an eye on data readouts from $KURA (Kura Oncology) and $BEAM (Beam Therapeutics). The focus this year is heavily on Menin inhibitors and next-gen gene editing for Sickle Cell"
X Link 2025-12-02T19:00Z XXX followers, XXX engagements

"Just in from ASH 2025: J&Js Tecvayli + Darzalex combo is showing a flattened OS curve in relapsed multiple myeloma. A potential functional cure signal in XX% of patients after X years. Biggest myeloma advance in decades. $JNJ"
X Link 2025-12-10T12:41Z XXX followers, XXX engagements

"Ginkgo Bioworks $DNA just secured a $47M contract from the U.S. Department of Energy to build the countrys first fully autonomous AI-powered microbial labs This is part of the Genesis Mission push to accelerate biofuels sustainable materials and next-gen therapeutics using robotics + AI. From years months for strain engineering Possibly a game-changing infrastructure move"
X Link 2025-12-09T22:10Z XXX followers, XXX engagements

"📰Roche just dropped blockbuster Phase X data for its oral SERD in early breast cancer: XX% lower risk of recurrence or death vs standard endocrine therapy. First big oral alternative to injectables in decades. $RHHBY $ROG.SW This ones going to move the needle in HR+ breast cancer treatment"
X Link 2025-12-10T20:53Z XXX followers, XX engagements